Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Citizen Petitions Targeting ANDAs Recede, But Concerns Over Resources Remain

Executive Summary

FDA worries about diverting resources to respond to 505(q) petitions, despite receiving lowest number in fiscal year 2015 since it began tracking requests.

Advertisement

Related Content

US Generic 'Breakthrough' Pathway Could Have Unintended Consequences
Generic Versions Of Rytary Should Meet 3 Extra Standards, Impax Says
Citizen Petitions Seeking To Delay Product Approvals Continue To Swamp FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS118999

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel